Nephros Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
36
- Stock Symbol
-
NEPH
- Investments
-
2
- Share Price
-
$3.05
- (As of Friday Closing)
Nephros General Information
Description
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
Contact Information
Website
www.nephros.comCorporate Office
- 380 Lackawanna Place
- South Orange, NJ 07079
- United States
Corporate Office
- 380 Lackawanna Place
- South Orange, NJ 07079
- United States
Nephros Stock Performance
As of 13-Nov-2026, Nephros’s stock price is $3.05. Its current market cap is $33.2M with 10.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.05 | $3.31 | $2.66 - $6.42 | $33.2M | 10.9M | 44.8K | $0.17 |
Nephros Financials Summary
As of 30-Sep-2026, Nephros has a trailing 12-month revenue of $21.6M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 36,466 | 47,841 | 14,535 | 32,436 |
| Revenue | 21,580 | 18,789 | 14,162 | 14,238 |
| EBITDA | 1,874 | 1,207 | 133 | (1,423) |
| Net Income | 1,911 | 1,194 | 74 | (1,575) |
| Total Assets | 15,305 | 13,641 | 11,210 | 11,861 |
| Total Debt | 774 | 1,063 | 1,411 | 1,836 |
Nephros Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Nephros Comparisons
Industry
Financing
Details
Nephros Competitors (8)
One of Nephros’s 8 competitors is Grouppo Medica, a Corporation company based in Medolla, Italy.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Grouppo Medica | Corporation | Medolla, Italy | ||||
| Nipro | Corporation | Osaka, Japan | ||||
| Ruhof | Private Equity-Backed | Mineola, NY | ||||
| Belimed | Corporation | Zug, Switzerland | ||||
| Fresenius Medical Care | Corporation | Bad Homburg, Germany |
Nephros Patents
Nephros Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210215577-A1 | Portable system and process thereof to rapidly detect the presence, family of origin and ratio of any bacteria and estimate the endotoxin-producing bacteria levels of a water sample | Inactive | 15-Jan-2020 | ||
| US-11964238-B2 | Method and apparatus for forward and reverse flushable filter system | Active | 13-Nov-2019 | ||
| US-20210138406-A1 | Method and apparatus for forward and reverse flushable filter system | Active | 13-Nov-2019 | ||
| US-20200340038-A1 | Portable system and process thereof to rapidly filter, concentrate, and detect waterborne pathogens | Inactive | 25-Apr-2019 | ||
| US-10821216-B1 | Method and apparatus for a hemodiafiltration module for use with a dialysis machine | Active | 03-Jul-2017 | A61M1/3413 |
Nephros Signals
Nephros Acquisitions (2)
Nephros’s most recent deal was a Merger/Acquisition with GenArraytion for . The deal was made on 09-Jul-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| GenArraytion | 09-Jul-2021 | Merger/Acquisition | Biotechnology | ||
| Biocon 1 | 31-Dec-2018 | Merger/Acquisition | Other Commercial Products |
Nephros ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
21 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Supplies
Subindustry
of 60
Rank
Percentile
Nephros Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Aether Water Systems | Henderson, NV | 2016 |
Nephros FAQs
-
When was Nephros founded?
Nephros was founded in 1997.
-
Where is Nephros headquartered?
Nephros is headquartered in South Orange, NJ.
-
What is the size of Nephros?
Nephros has 36 total employees.
-
What industry is Nephros in?
Nephros’s primary industry is Medical Supplies.
-
Is Nephros a private or public company?
Nephros is a Public company.
-
What is Nephros’s stock symbol?
The ticker symbol for Nephros is NEPH.
-
What is the current stock price of Nephros?
As of 13-Nov-2026 the stock price of Nephros is $3.05.
-
What is the current market cap of Nephros?
The current market capitalization of Nephros is $33.2M.
-
What is Nephros’s current revenue?
The trailing twelve month revenue for Nephros is $21.6M.
-
Who are Nephros’s competitors?
Grouppo Medica, Nipro, Ruhof, Belimed, and Fresenius Medical Care are some of the 8 competitors of Nephros.
-
What is Nephros’s annual earnings per share (EPS)?
Nephros’s EPS for 12 months was $0.17.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process